


FIGURE 1A




FIGURE 1B




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B




FIGURE 4A




FIGURE 4B




% HIV-1 X4 KON replication inhibition in PBMC
100
90
80
70
60
50
40
30
20
10
0
0.16
0.8
4
20
515H7 Mab concentration (µg/ml)

FIGURE 5






FIGURE 6A et 6B



C
CHO CXCR4 + c515H7 (1)
CHO CXCR4 + c515H7 (2)
CHO CXCR4 + c515H7 (3)
CHO CXCR4 (1)
% of basal signal
150
140
130
120
110
100
90
80
0
20
40
60
80
100
120
140
160
Time (s)

FIGURE 6C




Figure 7




Figure 8



% HIV virus replication inhibition in PBMC
100
90
80
70
60
50
40
30
20
10
0
KON
MN
92UG024
X4 virus
515H7 15 µg/ml
c515H7 15 µg/ml
301aE5 150 µg/ml

Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15



120
100
80
60
40
20
0
BRET (% of basal signal)
SDF1
(100 nM)
-
+
-
+
Irrelevant Mab
(20 µg/ml)
c515H7
(20 µg/ml)

Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22